Insulet Stock Forecast, Price & News

Insulet's stock was trading at $172.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PODD shares have increased by 29.1% and is now trading at $222.25.
View which stocks have been most impacted by COVID-19.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 10 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Insulet.

Insulet is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Insulet.

Insulet will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Insulet Co. (NASDAQ:PODD) announced its earnings results on Thursday, August, 6th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $0.23. The medical instruments supplier had revenue of $226.30 million for the quarter, compared to analysts' expectations of $212.41 million. Insulet had a net margin of 2.20% and a return on equity of 10.96%. The business's quarterly revenue was up 27.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.02 earnings per share.
View Insulet's earnings history.

Insulet issued an update on its FY 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $863.694-878.458 million, compared to the consensus revenue estimate of $849.76 million.

19 brokerages have issued twelve-month target prices for Insulet's shares. Their forecasts range from $165.00 to $260.00. On average, they anticipate Insulet's stock price to reach $223.88 in the next year. This suggests a possible upside of 0.7% from the stock's current price.
View analysts' price targets for Insulet.

Insulet saw a drop in short interest in the month of September. As of September 30th, there was short interest totaling 2,440,000 shares, a drop of 14.7% from the September 15th total of 2,860,000 shares. Based on an average daily trading volume, of 409,100 shares, the short-interest ratio is currently 6.0 days.
View Insulet's Short Interest.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Teleflex (TFX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), The Walt Disney (DIS), salesforce.com (CRM), Roku (ROKU) and The Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by a variety of retail and institutional investors. Top institutional investors include Standard Life Aberdeen plc (0.52%), KAMES CAPITAL plc (0.45%), Beacon Investment Advisory Services Inc. (0.36%), Columbus Circle Investors (0.35%), Scout Investments Inc. (0.17%) and Jag Capital Management LLC (0.14%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Columbus Circle Investors, KAMES CAPITAL plc, Nisa Investment Advisors LLC, HWG Holdings LP, Jag Capital Management LLC, Tributary Capital Management LLC, and Beacon Investment Advisory Services Inc.. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet.

PODD stock was acquired by a variety of institutional investors in the last quarter, including Standard Life Aberdeen plc, British Airways Pensions Investment Management Ltd, Kornitzer Capital Management Inc. KS, Assenagon Asset Management S.A., KBC Group NV, Handelsinvest Investeringsforvaltning, State of Alaska Department of Revenue, and Comerica Bank.
View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $222.25.

Insulet has a market capitalization of $14.59 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]